IPO Databook: Sichuan Biokin Pharmaceutical (HK) - Aug 2026

120 Views08 Aug 2026 10:10

SUMMARY

Sichuan Biokin Pharmaceutical Co., Ltd. is an integrated biopharmaceutical group founded in 1996, focused on developing oncology therapeutics using ADC, ARC, and TCE technologies.
Iza-bren is the world's first approved bispecific ADC, and the company has a global strategic license agreement with BMS, receiving US$800 million upfront.
The company reported RMB5,821,050 thousand revenue and a 95.0% gross profit margin in 2024, alongside a RMB1,053,618 thousand net loss in 2025.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream